BLOOMINGTON, Ind.–(BUSINESS WIRE)–Cook Medical has introduced the 140 mm-length Zilver® PTX® Drug-Eluting Peripheral Stent in both 6 and 7 mm diameters in the U.S. The longer length comes after an expanded indication approval by FDA to treat total lesion lengths up to 300 mm per patient. In addition, the product also received an extended shelf life of two years by the FDA.
The 140-mm length stents will enable physicians when applicable to treat lesions up to 270-mm with only two stents. In addition to this benefit, Zilver PTX has been shown to cut reinterventions by nearly half in 5 years, compared to a combination of bare-metal Zilver stents and PTA.1
“We’re happy to continually broaden the Zilver PTX product offering, giving physicians more options when treating superficial femoral artery disease based on the individual patient need,” said Mark Breedlove, vice president of Cook Medical’s vascular division.
Zilver PTX2 is the world’s first drug-eluting stent for treating peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and is the only drug-eluting SFA stent with five-year published data.
About Cook Medical
Since 1963 Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: patients, our employees and our communities. Find out more at www.cookmedical.com, and for the latest news, follow us on Twitter, Facebook and LinkedIn
1 Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX
2 Caution: U.S. federal law restricts this device to sale by or on the order of a physician (or properly licensed practitioner). Use of this drug-eluting peripheral stent carries the risks associated with peripheral artery stenting, including vascular complications and/or bleeding events. Refer to the Instructions for Use (IFU) for full prescribing information including information on potential adverse events, contraindications, warnings, precautions, and summary of clinical data.
Marsha Lovejoy, 812-320-6903 (mobile)
812-339-2235, ext. 10-2750 (office)
Global Manager, External Corporate Communications